International Myeloma Foundation: DVRd Regimen
May 01, 2026
May 01, 2026
NORTH HOLLYWOOD, California, May 1 -- The International Myeloma Foundation issued the following news on April 30, 2026:
* * *
The DVRd Regimen
This standard-of-care quadruplet combination is now FDA-approved for the majority of patients with newly diagnosed multiple myeloma
*
On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved the use of the quadruplet (4-drug) combination of Darzalex Faspro(R) (daratumumab + . . .
* * *
The DVRd Regimen
This standard-of-care quadruplet combination is now FDA-approved for the majority of patients with newly diagnosed multiple myeloma
*
On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved the use of the quadruplet (4-drug) combination of Darzalex Faspro(R) (daratumumab + . . .